公开(公告)号：US20220249657A1

公开(公告)日：2022-08-11

申请号：US17725199

申请日：2022-04-20

Applicant: RINAT NEUROSCIENCE CORP.

Inventor： Yasmina Noubia Abdiche ,  Helen Kim Cho ,  Wei-Hsien Ho ,  Karin Ute Jooss ,  Arvind Rajpal ,  Sawsan Youssef

IPC: A61K39/39 ,  A61K39/395 ,  A61K45/06 ,  A61K39/00 ,  C07K16/28

Abstract: The present invention provides antagonizing antibodies that bind to programmed cell death protein 1 (PD-1) and methods of using same. The anti-PD-1 antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.

公开(公告)号：US10155037B2

公开(公告)日：2018-12-18

申请号：US14958053

申请日：2015-12-03

Applicant: RINAT NEUROSCIENCE CORP.

Inventor： Yasmina Noubia Abdiche ,  Weihsien Ho ,  Arvind Rajpal ,  Sawsan Youssef

IPC: C07K16/28 ,  A61K39/395 ,  A61K39/39 ,  A61K45/06 ,  A61K39/00

Abstract: The present invention provides antagonizing antibodies that bind to programmed cell death protein 1 (PD-1) and methods of using same. The anti-PD-1 antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.

公开(公告)号：US09175093B2

公开(公告)日：2015-11-03

申请号：US13857063

申请日：2013-04-04

Applicant: RINAT NEUROSCIENCE CORP. ,  PFIZER INC.

Inventor： Hong Liang ,  Yasmina Noubia Abdiche ,  Javier Fernando Chaparro Riggers ,  Bruce Charles Gomes ,  Julie Jia Li Hawkins ,  Jaume Pons ,  Xiayang Qiu ,  Pavel Strop ,  Yuli Wang

IPC: A61K39/395 ,  C07K16/40 ,  A61K45/06 ,  A61K39/00

CPC classification number: C07K16/40 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2299/00 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia.

Abstract translation: 本发明提供了与抗蛋白转化酶枯草杆菌蛋白酶Kexin 9型（PCSK9）结合的拮抗抗体，其抗原结合部分和适体。 还提供了针对肽的抗体，其中抗体结合PCSK9。 本发明还提供了获得这样的抗体和抗体编码核酸的方法。 本发明还涉及使用这些抗体及其抗原结合部分来降低LDL-胆固醇水平和/或用于治疗和/或预防心血管疾病（包括治疗高胆固醇血症）的治疗方法。

公开(公告)号：US20200368349A1

公开(公告)日：2020-11-26

申请号：US16847229

申请日：2020-04-13

Applicant: RINAT NEUROSCIENCE CORP.

Inventor： Yasmina Noubia Abdiche ,  Helen Kim Cho ,  Wei-Hsien Ho ,  Karin Ute Jooss ,  Arvind Rajpal ,  Sawsan Youssef

IPC: A61K39/39 ,  A61K39/395 ,  A61K45/06 ,  A61K39/00 ,  C07K16/28

Abstract: The present invention provides antagonizing antibodies that bind to programmed cell death protein 1 (PD-1) and methods of using same. The anti-PD-1 antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.

公开(公告)号：US11338035B2

公开(公告)日：2022-05-24

申请号：US16847229

申请日：2020-04-13

Applicant: RINAT NEUROSCIENCE CORP.

Inventor： Yasmina Noubia Abdiche ,  Helen Kim Cho ,  Wei-Hsien Ho ,  Karin Ute Jooss ,  Arvind Rajpal ,  Sawsan Youssef

IPC: C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  A61K39/39 ,  A61K45/06 ,  A61K39/00

Abstract: The present invention provides antagonizing antibodies that bind to programmed cell death protein 1 (PD-1) and methods of using same. The anti-PD-1 antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.

公开(公告)号：US10660953B2

公开(公告)日：2020-05-26

申请号：US16188120

申请日：2018-11-12

Applicant: RINAT NEUROSCIENCE CORP.

Inventor： Yasmina Noubia Abdiche ,  Helen Kim Cho ,  Weihsien Ho ,  Karin Ute Jooss ,  Arvind Rajpal ,  Sawsan Youssef

IPC: C07K16/28 ,  A61K39/395 ,  A61K39/39 ,  A61K45/06 ,  A61K39/00

Abstract: The present invention provides antagonizing antibodies that bind to programmed cell death protein 1 (PD-1) and methods of using same. The anti-PD-1 antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.